SOTIO initiates first-in-human clinical trial with IL-15 superagonist SO-C101
SOTIO and Cytune Pharma, members of the PPF Group, announce today the first dosing of cancer patients with SO-C101, a superagonist fusion protein of interleukin IL-15. The phase I/Ib study (SC103) will evaluate the safety and preliminary efficacy of SO-C101 in patients with selected advanced/metastatic solid tumors.
The first patient was treated with SO-C101 at the Institute Gustave Roussy (France). The SC103 clinical trial will also enrol patients in the Vall d’Hebron cancer center (Spain) and, subject to obtaining all the necessary approvals, at the Yale Cancer Center in New Haven, CT and MD Anderson Cancer Center in Houston, TX. Cytune Pharma is responsible for the clinical development of SO-C101, SOTIO is sponsor of the SC103 clinical trial.
Aurélien Marabelle, M.D., Ph.D., coordinating investigator of the phase I/Ib trial said: “I am very pleased that our medical center has enrolled the first patient in this important clinical trial. We believe that SO-C101 has the potential to make a life-changing difference to many patients with difficult-to-treat forms of cancer. I am looking forward to further advancing this innovative therapy.“
“SO-C101 is a very innovative approach which has been validated for its efficacy and safety in preclinical experiments. Since SO-C101 is an ideal combination partner for checkpoint inhibitors, monoclonal antibodies and other well established therapies, the planning for additional combination trials is already ongoing,” said Radek Spisek, M.D., Ph.D., CEO of SOTIO.
“I’m excited that after 12 years of research and development at Cytune Pharma, which was based on previous research from INSERM and the University of Nantes and supported by Bpifrance and Atlanpole Biotherapies, our invention has now entered the clinical development phase. I hope that SO-C101 will become a treatment for cancer patients in the future,” adds David Bechard, Ph.D., President and COO of Cytune Pharma.
Description of clinical trial
SC103 (Eudra CT: 2012-002814-38): A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in selected patients with advanced/metastatic solid tumors. SOTIO received a positive decision allowing launch of SC103 clinical trial within the EU Voluntary Harmonisation Procedure (VHP) in February 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190711005058/en/
Contact information
Richard Kapsa
Head of Communication
T: (+420) 224 174 448
M: (+420) 603 280 971
kapsa@sotio.com
Webpage: https://www.sotio.com/news-publications/news
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
nCipher Introduces Cloud-first Architecture, Bringing Security and Control to Public and Private Clouds29.1.2020 11:00:00 EET | Press release
nCipher Security, an Entrust Datacard company and provider of trust, integrity and control for business critical information and applications, announces two new additions to its nShield® hardware security module (HSM) portfolio – nShield Web Services Option Pack and nShield Container Option Pack – that make it simpler to deploy applications in the cloud and bring greater security and control to public and private clouds. nShield Web Services Option Pack simplifies deployment for cloud-first data centres. nShield Web Services Option Pack provides a REST API between applications requiring cryptographic key and data protection services and nShield HSMs, enabling seamless application deployment underpinned by high-assurance nShield HSMs, which can dynamically scale to meet the needs of cloud-ready data centers. Customers can also use their own load balancing appliances to handle the HSM workload, simplifying the HSM deployment and configuration, and ensuring the best utilization of their H
Denenchofufutaba Gakuen, NTT Group Start a Joint Study to Create Smart Campus Solutions29.1.2020 10:32:00 EET | Press release
NTT Group (Nippon Telegraph and Telephone Corporation (Hereinafter, NTT), NTT DATA Corporation, NTT COMWARE Corporation, NTT Communications Corporation, NTT Ltd., Nippon Telegraph and Telephone East Corporation (Hereinafter, NTT East)) will begin a joint study with Denenchofufutaba Gakuen in order to develop smart campus solutions that will provide safety and security at schools. NTT Group implements technology of public safety solution that will draw on the proven implementation for the City of Las Vegas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200128005916/en/ Solution Overview (Graphic: Business Wire) 1. Background In recent years, there have been several crimes and incidents involving students in school facilities, and resulting in requests to improve safety measures in addition to crime prevention activities by national and local governments. Furthermore, with the introduction of new educational guidelines, the w
Panasonic Develops High-Power Blue WBC Technology to Revolutionize DDL Applications on Microfabrication29.1.2020 09:11:00 EET | Press release
On January 29, 2020, Panasonic Corporation announced it has succeeded in demonstrating the world's highest brightness blue laser. This has been achieved by using the wavelength beam combining (WBC) technology [1] on a direct diode laser (DDL) to produce a high quality output beam [2]. With this technology, power scaling is enabled while maintaining the beam quality by simply increasing the number of laser sources. This demonstration opens the door to laser intensities that could be two orders of magnitude higher than conventional blue laser systems. This technology will contribute to the emerging microfabrication processes, whose demand is expected to grow in industrial applications, such as in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200128005907/en/ Wavelength Beam Combining (WBC) technology (Graphic: Business Wire) The automotive industry is moving towards “electrification” and “miniaturizat
NTT Group to Launch Asia's First Smart City Proof of Concept Collaborating with Cyberview and Allo in Malaysia29.1.2020 09:00:00 EET | Press release
As part of the Japanese Ministry of Internal Affairs and Communications’ FY 2019 project "Research on Smart City Model for Solving Social Problems in Malaysia", based on the smart city initiatives which has been started with the City of Las Vegas, United States, NTT Group (Nippon Telegraph and Telephone Corporation (Hereinafter, NTT), NTT Communications Corporation, NTT Ltd., InfoCom Research, Inc., NTT DATA Corporation, NTT COMWARE Corporation) will conduct Asia's one of the first Smart City Proof of Concept (PoC) in the Cyberjaya area of Malaysia from February 2020, in cooperation with local stakeholders. Through this PoC, NTT Group aims to establish a sustainable business model while verifying the possibility of solving social issues in Asia, utilizing the technologies and know-how accumulated in the smart city field in the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200128005904/en/ (Graphic: Business W
Kioxia Appoints Masaki Momodomi as Chief Technology Officer29.1.2020 07:00:00 EET | Press release
Kioxia Holdings Corporation today announced the appointment of Masaki Momodomi as Chief Technology Officer (CTO) of Kioxia, effective immediately. Mr. Momodomi fills the role of Former CTO Nobuo Hayasaka, who has been appointed as President and Chief Executive Officer (CEO) of Kioxia. Mr. Momodomi has an accomplished background in the memory industry, bringing over 40 years of experience across roles at Kioxia, Toshiba Memory and Toshiba Corporation. Following Toshiba Memory’s separation from Toshiba Corporation, Mr. Momodomi was named director of Toshiba Memory, now Kioxia’s Institute of Memory Technology Research and Development. Previously, he served as director of Toshiba Corporation’s Center of Semiconductor Research and Development. A pioneer in the memory field, in 1987, Mr. Momodomi co-authored a dissertation on Toshiba’s invention of NAND Flash memory, playing a vital role in the exponential growth of the now ubiquitous technology. Mr. Momodomi graduated from Kyushu University
Kioxia Appoints Nobuo Hayasaka as President and CEO29.1.2020 07:00:00 EET | Press release
Kioxia Holdings Corporation today announced that the Board of Directors has appointed Nobuo Hayasaka as President and CEO of Kioxia, effective immediately. Dr. Hayasaka has served as Acting President and CEO since July 12, 2019, during Former President and CEO Yasuo Naruke’s medical leave of absence. Dr. Naruke notified the company’s Board of Directors of his desire to step down as President, CEO and member of the board as he continues to focus on his health. “Dr. Naruke has been an outstanding leader for our company over many years, and we thank him for the invaluable contribution he has made to shaping us into the company we are today.” said Stacy J. Smith, Executive Chairman of Kioxia. “This year presents an exciting opportunity for Kioxia, and President Hayasaka has the skills, experience and the full backing of our Board of Directors, management and employees as we move toward a new era of memory. I look forward to working closely with President Hayasaka and the rest of the execut
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom